COUMADIN

Compare COUMADIN  to:
Compare
Compare

Generic Name for COUMADIN

Warfarin sodium 1mg, 2mg, 2½mg, 3mg, 4mg, 5mg, 6mg, 7½mg, 10mg (dye-free); scored tabs.

Legal Classification:

Rx

Pharmacological Class for COUMADIN

Coumarin anticoagulant.

Manufacturer of COUMADIN

Bristol-Myers Squibb

Indications for COUMADIN

Thromboembolic disorders. Thromboembolic complications from atrial fibrillation, cardiac valve replacement. Reduce risk of death, recurrent MIs, and thromboembolic events post-MI.

Adult dose for COUMADIN

Individualize. IV: give as slow bolus dose over 1–2 minutes into a peripheral vein. ≥18yrs: Initially 2–5mg orally or IV daily. Usual maintenance: 2–10mg daily. Variations in CYP2C9 or VKORC1 enzymes, elderly, debilitated: use lower initial dose. Monitor PT; adjust dose and interval according to INR and/or PT (INR preferred). Converting from heparin: see literature.

Children's dosing for COUMADIN

<18yrs: see literature.

Also:

Contraindications for COUMADIN

Hazardous hemorrhagic conditions or treatments. Malignant hypertension. Blood dyscrasias. Unsupervised senile, alcoholic, uncooperative, or psychotic patients. CNS, ophthalmic, or traumatic surgery. Major regional, lumbar block anesthesia, spinal puncture. Inadequate lab facilities. Pregnancy (Cat.X).

Precautions for COUMADIN

Monitor PT/INR. Hepatic or renal insufficiency. Infection. Trauma. Diabetes. Hypertension. CHF. Edema. Hyperlipidemia. Thyroid disorders. Collagen vascular disease. Protein C deficiency. Heparin-induced thrombocytopenia. Polycythemia vera. Cancer. Vasculitis. Indwelling catheter. Fever. Discontinue if tissue necrosis or systemic cholesterol microembolization occurs. Gangrene. Diarrhea. Disturbances of intestinal flora. Steatorrhea. Dental procedures. Elderly. Asian. Debilitated. Anticoagulation may persist 2–5 days after discontinuation. Write ℞ using fractions rather than decimals. Nursing mothers.

Interactions for COUMADIN

See literature. Potentiated by plasma protein bound drugs, analgesics, antiarrhythmics, antibiotics, β-blockers, diuretics, proton pump inhibitors, psychostimulants, thyroid drugs, uricosurics, vaccines, fibric acid derivatives, vitamin K deficiency, others. Antagonized by antacids, anxiolytics, antihistamines, antipsychotics, barbiturates, statins, hepatic enzyme inducers, oral contraceptives, diets high in vitamin K, others. Potentiates hypoglycemics, anticonvulsants, others. Caution with drugs that may cause hemorrhage (eg, NSAIDs, aspirin), herbal supplements (eg, ginkgo biloba, ginseng, St. John's wort), alcohol. Cholestatic hepatitis with concomitant ticlopidine.

Adverse Reactions for COUMADIN

Tissue or organ hemorrhage, skin or tissue necrosis, hypersensitivity reactions, systemic cholesterol microembolization, purple toes syndrome, vasculitis, hepatic disorders, fever, dermatitis, urticaria, abdominal pain, asthenia, GI upset, headache, pruritus, alopecia, paresthesias.

How is COUMADIN supplied?

Tabs 1mg, 2mg, 2½mg, 3mg, 4mg, 5mg, 6mg—100, 1000
7½mg, 10mg—100
Inj (5mg vial)—6

Related Disease:

Coagulation disorders

Related Resources

Iprivask available for prevention of deep vein thrombosis

March 01, 2010

Canyon Pharmaceuticals announced that Iprivask (desirudin for injection), a direct thrombin inhibitor, has been made available for the prevention of deep vein thrombosis (DVT), which may lead to pulmonary embolism, in patients undergoing elective hip replacement surgery.

FDA cancer drug approval rate reviewed in JNCI

February 19, 2010

The FDA's Office of Oncology Drug Products approved 53 new indications for the use of oncology and hematology drugs and biologics from July 2005 to the end of 2007.

Orphan drug designation granted to QPI-1002 for delayed graft function (DGF) in kidney transplant

February 16, 2010

Quark Pharmaceuticals was granted orphan drug designation by the FDA for its synthetic siRNA drug candidate, QPI-1002 (I5NP), for the prophylaxis of delayed graft function (DGF) in kidney transplant patients.

Phase 3 study of edoxaban for recurrent venous thromboembolic (VTE)

February 03, 2010

Daiichi Sankyo announced it has initiated a Phase 3 trial for edoxaban for the reduction of recurrent venous thromboembolic (VTE) complications in patients with deep vein thrombosis (DVT) and/or pulmonary embolism (PE).

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).